Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

NCT: NCT05092516 · ACTIVE_NOT_RECRUITING

NCT IDNCT05092516
StatusACTIVE_NOT_RECRUITING
Start Date2022-06-07
Completion2026-12-31
SponsorMassachusetts General Hospital (OTHER)
First posted
Last updated

Brief Summary

The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑